– Vir Biotechnology (VIR) to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results